tiprankstipranks
Immunic, Inc. (IMUX)
NASDAQ:IMUX
US Market
IMUX
Immunic
RESEARCH TOOLSreports
Want to see IMUX full AI Analyst Report?

Immunic (IMUX) Stock Forecast & Price Target

2,240 Followers
See the Price Targets and Ratings of:

IMUX Analyst Ratings

Strong Buy
7Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Immunic
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMUX Stock 12 Month Forecast

Average Price Target

$29.80
▲(2880.00% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Immunic in the last 3 months. The average price target is $29.80 with a high forecast of $56.00 and a low forecast of $19.00. The average price target represents a 2880.00% change from the last price of $1.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","57":"$57","17.25":"$17.25","30.5":"$30.5","43.75":"$43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,17.25,30.5,43.75,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.13,18.273846153846154,21.417692307692306,24.56153846153846,27.705384615384617,30.84923076923077,33.99307692307692,37.136923076923075,40.28076923076923,43.424615384615386,46.568461538461534,49.71230769230769,52.856153846153845,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.13,16.25846153846154,17.38692307692308,18.515384615384615,19.643846153846155,20.77230769230769,21.90076923076923,23.02923076923077,24.157692307692308,25.286153846153844,26.414615384615384,27.543076923076924,28.67153846153846,{"y":29.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.13,15.427692307692308,15.725384615384616,16.023076923076925,16.32076923076923,16.61846153846154,16.916153846153847,17.213846153846156,17.51153846153846,17.80923076923077,18.106923076923078,18.404615384615386,18.70230769230769,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.904,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.315,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.599,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.788,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.337,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.539,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.599,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.65,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.13,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$56.00Average Price Target$29.80Lowest Price Target$19.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IMUX
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$22
Buy
2100.00%
Upside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (NASDAQ: COYA), Nurix Therapeutics (NASDAQ: NRIX) and Immunic (NASDAQ: IMUX)
Stifel Nicolaus Analyst forecast on IMUX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$25
Buy
2400.00%
Upside
Reiterated
05/28/26
Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)
B. Riley Securities Analyst forecast on IMUX
William Wood
B. Riley Securities
B. Riley Securities
$40→$27
Buy
2600.00%
Upside
Reiterated
05/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (NASDAQ: CRDF), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Immunic (NASDAQ: IMUX)
LifeSci Capital Analyst forecast on IMUX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$56
Buy
5500.00%
Upside
Reiterated
05/16/26
Immunic (IMUX) Gets a Buy from LifeSci Capital
Roth MKM Analyst forecast on IMUX
Boobalan Pachaiyappan
Roth MKM
Roth MKM
$19
Buy
1800.00%
Upside
Assigned
05/14/26
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Tenon Medical, Inc. (TNON)
William Blair Analyst forecast on IMUX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and Medline (NASDAQ: MDLN)
D. Boral Capital Analyst forecast on IMUX
Jason Kolbert
D. Boral Capital
D. Boral Capital
―
Hold
―
Downgraded
04/15/26
Immunic downgraded to Hold from Buy at D. Boral CapitalImmunic downgraded to Hold from Buy at D. Boral Capital
Guggenheim Analyst forecast on IMUX
Yatin Suneja
Guggenheim
Guggenheim
$70
Buy
6900.00%
Upside
Initiated
03/24/26
Immunic initiated with a Buy at GuggenheimImmunic initiated with a Buy at Guggenheim
Wolfe Research Analyst forecast on IMUX
Rudy Li
Wolfe Research
Wolfe Research
$30
Buy
2900.00%
Upside
Initiated
12/31/25
Immunic (IMUX) Has a New Rating from Chardan Capital
Ladenburg Thalmann & Co. Analyst forecast on IMUX
Aydin Huseynov
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$30
Buy
2900.00%
Upside
Initiated
10/16/25
Immunic initiated with a Buy at LadenburgImmunic initiated with a Buy at Ladenburg
Jefferies Analyst forecast on IMUX
Faisal Khurshid
Jefferies
Jefferies
―
Buy
―
Reiterated
09/25/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IMUX
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$22
Buy
2100.00%
Upside
Reiterated
06/08/26
Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (NASDAQ: COYA), Nurix Therapeutics (NASDAQ: NRIX) and Immunic (NASDAQ: IMUX)
Stifel Nicolaus Analyst forecast on IMUX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$25
Buy
2400.00%
Upside
Reiterated
05/28/26
Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)
B. Riley Securities Analyst forecast on IMUX
William Wood
B. Riley Securities
B. Riley Securities
$40→$27
Buy
2600.00%
Upside
Reiterated
05/22/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (NASDAQ: CRDF), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Immunic (NASDAQ: IMUX)
LifeSci Capital Analyst forecast on IMUX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$56
Buy
5500.00%
Upside
Reiterated
05/16/26
Immunic (IMUX) Gets a Buy from LifeSci Capital
Roth MKM Analyst forecast on IMUX
Boobalan Pachaiyappan
Roth MKM
Roth MKM
$19
Buy
1800.00%
Upside
Assigned
05/14/26
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Tenon Medical, Inc. (TNON)
William Blair Analyst forecast on IMUX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and Medline (NASDAQ: MDLN)
D. Boral Capital Analyst forecast on IMUX
Jason Kolbert
D. Boral Capital
D. Boral Capital
―
Hold
―
Downgraded
04/15/26
Immunic downgraded to Hold from Buy at D. Boral CapitalImmunic downgraded to Hold from Buy at D. Boral Capital
Guggenheim Analyst forecast on IMUX
Yatin Suneja
Guggenheim
Guggenheim
$70
Buy
6900.00%
Upside
Initiated
03/24/26
Immunic initiated with a Buy at GuggenheimImmunic initiated with a Buy at Guggenheim
Wolfe Research Analyst forecast on IMUX
Rudy Li
Wolfe Research
Wolfe Research
$30
Buy
2900.00%
Upside
Initiated
12/31/25
Immunic (IMUX) Has a New Rating from Chardan Capital
Ladenburg Thalmann & Co. Analyst forecast on IMUX
Aydin Huseynov
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$30
Buy
2900.00%
Upside
Initiated
10/16/25
Immunic initiated with a Buy at LadenburgImmunic initiated with a Buy at Ladenburg
Jefferies Analyst forecast on IMUX
Faisal Khurshid
Jefferies
Jefferies
―
Buy
―
Reiterated
09/25/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunic

3 Months
Myles MinterWilliam Blair
Success Rate
7/11 ratings generated profit
64%
Average Return
+29.65%
Copying Myles Minter's trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +29.65% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
10/11 ratings generated profit
91%
Average Return
+69.45%
Copying Myles Minter's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +69.45% per trade.
2 Years
Myles MinterWilliam Blair
Success Rate
11/11 ratings generated profit
100%
Average Return
+79.88%
Copying Myles Minter's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +79.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMUX Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
2
4
6
15
13
Buy
5
5
5
3
2
Hold
0
0
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
9
13
20
17
In the current month, IMUX has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IMUX average Analyst price target in the past 3 months is 29.80.
Each month's total comprises the sum of three months' worth of ratings.

IMUX Financial Forecast

IMUX Earnings Forecast

Next quarter’s earnings estimate for IMUX is -$1.18 with a range of -$2.41 to -$0.63. The previous quarter’s EPS was -$1.08. IMUX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMUX has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMUX is -$1.18 with a range of -$2.41 to -$0.63. The previous quarter’s EPS was -$1.08. IMUX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IMUX has Performed in-line its overall industry.
No data currently available

IMUX Sales Forecast

Next quarter’s sales forecast for IMUX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMUX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMUX has Performed in-line its overall industry.
Next quarter’s sales forecast for IMUX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMUX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IMUX has Performed in-line its overall industry.

IMUX Stock Forecast FAQ

What is IMUX’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunic, Inc.’s 12-month average price target is 29.80.
    What is IMUX’s upside potential, based on the analysts’ average price target?
    Immunic, Inc. has 2880.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMUX a Buy, Sell or Hold?
          Immunic, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Immunic, Inc.’s price target?
            The average price target for Immunic, Inc. is 29.80. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $56.00 ,the lowest forecast is $19.00. The average price target represents 2880.00% Increase from the current price of $1.
              What do analysts say about Immunic, Inc.?
              Immunic, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of IMUX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.